Abstract:
A system on chip (10) comprises a responder unit (14) comprising a set of responder elements (15) and an access control unit (18) associated with an authorization list (38) and the responder unit (14). An entry of the authorization list (38) defines a set of access requirements in relation to an address space identifying at least part of the responder unit (14). The access control unit (18) is arranged to: receive a request for access (34) to a target responder element (15') among the responder elements (15) of the responder unit (14), determine the corresponding set of access requirements for the received access request from the authorization list (38), and evaluate the request for access (34) with respect to the determined set of access requirements and generate a first request evaluation result (56). A protection unit (36) associated with the responder unit (14) is arranged to: provide a group assignment (40) assigning a group (G1, G2, G3,...) to each of the responder elements (15) of the responder unit (14), provide a group authorization list (42), an entry of the group authorization list (42) defining a set of group access requirements for the group assigned, receive the request for access (34) to the target responder element (15'), determine the group assigned to the target responder element (15') from the group assignment (40) and further determine the set of group access requirements from the group authorization list (42) for the group assigned. The system-on-chip also evaluates the request with respect to the determined set of group access requirements and generates a second request evaluation result (58). Interaction with the target responder element (15') is controlled in response to the first and/or second evaluation result (56, 58).
Abstract:
Gegenstand der vorliegenden Erfindung sind neue CGRP-Antagonisten der allgemeinen Formel (I) in der R 1 , R 2 , R 3 , R a , R b , R c , X, Y und Z wie nachstehend erwähnt definiert sind, deren individuelle Diastereomere, deren individuelle Enantiomere und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung.
Abstract:
A system comprises at least two random access memory (RAM) elements arranged to store data redundantly. The system further comprises RA M routing logic comprising comparison logic operably coupled to the at least two RAM elements and arranged to compare redundant data read from the at least two RAM elements, and check and validation logic, independent of the RAM routing logic, operably coupled to the at least two RAM elements and arranged to additionally detect an error in the redundant data read from th e at least two RAM elements and provide an error indication signal to the RAM routing logic in re sponse thereto. The RAM routing logic further comprises selection logic arranged to dynamically select redundant data from one of the at least two RAM elements based on the comparison of t he redundant data and the error indication signal.
Abstract:
The invention relates to novel CGRP antagonists of general formulas (Ia) and (Ib) in which R1, R2, R3, R4, and R5 are defined as indicated below, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures, and salts thereof, and the hydrates of the salts, especially the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing said compounds, the use thereof, and methods for the production thereof.
Abstract:
A system (100) comprises a first master element (110, 910); and at least one shared communication element (130, 940) arranged to operably couple the first master element (110, 910) to at least one slave element (140, 150, 170). The system (100) further comprises at least one validation element (180, 190, 960, 970, 980, 990) located on at least one further validation path (114, 124, 117) located between the first master element (110, 910) and the at least one slave element (140, 150, 170), wherein the at least one validation element (180, 190, 960, 970, 980, 990) is arranged to validate at least one of: at least one access request by the first master element (110, 910); and a response to an access request from the at least one slave element (140, 150, 170).
Abstract:
Gegenstand der vorliegenden Erfindung sind neue CGRP-Antagonisten der allgemeinen Formel (I): in der U, V, X, Y, R 1 , R 2 und R 3 wie nachstehend erwähnt definiert sind, deren Tautomere, deren Isomere, deren Diastereomere, deren Enantiomere, deren Hydrate, deren Gemische und deren Salze sowie die Hydrate der Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung.
Abstract:
The invention relates to a metal sheet, or a component made of a metallic material, comprising a layer system on the surface with at least the following layers: a) a conversion layer, comprising no more than 1 mg chromium per m 2 , b) a layer of a cross-linked organic polymer system with a thickness in the range of 0.5 to 2.5 µm, comprising, in relation to the total mass of said layer, 2 to 25 wt.% of an electrically conductive pigment having a specific weight of 3 g/cm 3 maximum, however no more than 5 wt. % of the electrically conductive pigment having a specific weight of more than 3 g/m 3 . A coating material and a coating method for the production of the layer b).
Abstract:
The present invention relates to compounds of general formula (I) wherein the groups and radicals B, k, L, U,V, W, X, Y, Z, R 1 , R 2 , have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH- receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
Abstract:
The invention relates to CGRP antagonists of general formula (I), in which R 1 , R 2 , R 3 and R 4 are described in Claim 1, to the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts thereof, to the hydrates of the salts, particularly their physiologically compatible salts with inorganic or organic acids or bases, to the compounds of general formula (I), in which one or more hydrogen atoms are exchanged for deuterium, to medicaments containing these compounds, the use thereof, and to methods for producing them.
Abstract:
Gegenstand der vorliegenden Erfindung sind die CGRP-Antagonisten der allgemeinen Formel I in der R1, R2, R3 und R4 wie in Anspruch 1 definiert sind, deren Tautomere, deren Isomere, deren Diastereomere, deren Enantiomere, deren Hydrate, deren Gemische und deren Salze sowie die Hydrate der Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, sowie diejenigen Verbin¬ dungen der allgemeinen Formel I, in denen ein oder mehrere Wasserstoffatome durch Deuterium ausgetauscht sind, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung.